1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Sato, A.
Kawaguchi, K.
Kimura, K.
Tanimura, R.
Sone, S.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
A peptide mimetic of IFN, the first proof of a small peptidic agonist for heterodimeric cytokine receptor
10.2210/pdb1id6/pdb
pdb_00001id6
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
1784.942
SYR6
1
syn
polymer
no
no
SVQARWEAAFDLDLY
SVQARWEAAFDLDLY
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
2002-04-10
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
RCSB
Y
PDBJ
2001-04-04
REL
REL
chemically synthesized
sample
These structures were determined using standard 2D homonuclear techniques.
structures with the least restraint violations
750
11
DQF-COSY
TOCSY
2D NOESY
ambient
293
K
The structures are based on 66 NOE-derived
distance constraints.
4D simulated annealing
3
fewest violations
2.0mM SYR6; deuterated dimethyl sulfoxide 100%
deuterated dimethyl sulfoxide 100%
Morikawa, S. et. al.
structure solution
EMMBOSS
5.0
Morikawa, S. et. al.
refinement
EMMBOSS
5.0
600
Varian
INOVA
SER
1
n
1
SER
1
A
VAL
2
n
2
VAL
2
A
GLN
3
n
3
GLN
3
A
ALA
4
n
4
ALA
4
A
ARG
5
n
5
ARG
5
A
TRP
6
n
6
TRP
6
A
GLU
7
n
7
GLU
7
A
ALA
8
n
8
ALA
8
A
ALA
9
n
9
ALA
9
A
PHE
10
n
10
PHE
10
A
ASP
11
n
11
ASP
11
A
LEU
12
n
12
LEU
12
A
ASP
13
n
13
ASP
13
A
LEU
14
n
14
LEU
14
A
TYR
15
n
15
TYR
15
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
VAL
2
-13.10
1
A
ARG
5
11.53
1
A
TRP
6
13.07
1
A
ASP
11
-13.46
1
A
LEU
12
-13.89
2
A
GLN
3
-12.85
2
A
ALA
4
-12.58
3
A
GLN
3
-12.38
3
A
ARG
5
10.09
4
A
ALA
4
-17.91
4
A
TRP
6
11.19
4
A
GLU
7
-10.27
4
A
ALA
8
-12.26
4
A
PHE
10
14.26
4
A
LEU
12
-14.08
5
A
ALA
4
-10.62
5
A
ARG
5
11.44
6
A
ARG
5
12.50
6
A
TRP
6
10.79
6
A
ALA
8
-10.98
7
A
GLN
3
-12.61
7
A
ARG
5
10.29
7
A
ALA
8
-11.11
7
A
LEU
12
-10.86
8
A
VAL
2
-11.06
8
A
GLN
3
-12.45
8
A
ALA
4
12.96
8
A
ARG
5
14.16
8
A
PHE
10
11.38
9
A
VAL
2
-10.67
9
A
GLN
3
-11.39
9
A
ARG
5
11.35
9
A
ALA
8
-11.94
10
A
VAL
2
-10.81
11
A
SER
1
-11.27
11
A
VAL
2
-11.35
11
A
ARG
5
12.74
1
A
VAL
2
63.55
-103.42
1
A
GLN
3
-164.17
-36.26
1
A
ALA
4
53.14
-176.35
1
A
ARG
5
48.16
27.17
1
A
TRP
6
-162.29
-154.32
1
A
GLU
7
-32.51
96.01
1
A
ALA
8
57.81
-92.95
1
A
ALA
9
170.39
127.10
1
A
ASP
11
175.90
-30.49
1
A
LEU
14
59.80
78.82
2
A
VAL
2
39.32
-107.22
2
A
GLN
3
-159.23
-33.57
2
A
ALA
4
60.83
-179.95
2
A
ARG
5
34.77
43.47
2
A
TRP
6
-154.09
-151.59
2
A
GLU
7
-38.30
-81.18
2
A
ALA
9
-41.02
156.13
2
A
PHE
10
-142.41
-87.88
2
A
LEU
12
-142.97
-48.57
2
A
ASP
13
39.57
51.67
2
A
LEU
14
78.68
111.30
3
A
VAL
2
-73.84
-98.18
3
A
GLN
3
-133.52
-39.87
3
A
ALA
4
51.36
-175.11
3
A
ARG
5
37.15
42.23
3
A
TRP
6
-156.45
-149.06
3
A
GLU
7
-50.81
-96.37
3
A
PHE
10
-119.32
-86.20
3
A
ASP
13
37.68
29.67
4
A
VAL
2
-93.22
-79.43
4
A
GLN
3
-145.59
-35.51
4
A
ALA
4
65.09
179.35
4
A
ARG
5
31.72
40.13
4
A
TRP
6
-142.68
-153.30
4
A
GLU
7
-33.99
-31.30
4
A
ALA
8
-168.00
-76.38
4
A
ALA
9
159.94
142.74
4
A
PHE
10
-126.54
-95.84
4
A
LEU
12
-130.01
-62.52
4
A
ASP
13
39.55
56.52
4
A
LEU
14
-97.20
41.96
5
A
VAL
2
-83.86
-92.94
5
A
GLN
3
-146.22
-45.10
5
A
ALA
4
55.15
-171.24
5
A
ARG
5
34.69
35.66
5
A
TRP
6
-147.82
-148.34
5
A
GLU
7
-36.61
-29.96
5
A
ALA
8
-169.44
-68.61
5
A
ALA
9
159.61
120.17
5
A
PHE
10
-131.44
-71.78
5
A
LEU
12
-172.51
-43.98
6
A
VAL
2
37.91
-100.41
6
A
GLN
3
-157.30
-61.34
6
A
ALA
4
76.99
-15.38
6
A
ARG
5
-98.94
40.07
6
A
TRP
6
-141.85
-145.25
6
A
GLU
7
-35.72
-31.22
6
A
ALA
8
-163.63
-75.86
6
A
ALA
9
175.63
133.77
6
A
PHE
10
-112.53
-92.67
6
A
LEU
12
-104.68
-75.10
6
A
LEU
14
-93.84
45.56
7
A
VAL
2
38.63
-110.13
7
A
GLN
3
-166.83
-31.41
7
A
ALA
4
47.95
174.43
7
A
TRP
6
-162.16
-148.46
7
A
GLU
7
-36.69
-75.45
7
A
ALA
8
-105.57
-93.67
7
A
ALA
9
164.97
160.99
7
A
PHE
10
-130.40
-84.69
7
A
LEU
12
-160.42
30.98
7
A
LEU
14
-151.86
-69.62
8
A
VAL
2
-69.04
-99.22
8
A
GLN
3
-170.74
-36.21
8
A
ALA
4
81.10
-62.88
8
A
TRP
6
-164.87
-148.51
8
A
GLU
7
-44.33
-96.80
8
A
ALA
9
-36.90
148.23
8
A
PHE
10
-129.03
-83.92
8
A
LEU
14
168.66
49.05
9
A
VAL
2
-68.60
-100.17
9
A
GLN
3
-159.55
-35.66
9
A
ALA
4
47.29
173.56
9
A
TRP
6
-165.83
-148.71
9
A
GLU
7
-35.67
-71.07
9
A
ALA
8
-111.05
-93.26
9
A
ALA
9
163.97
151.57
9
A
PHE
10
-109.56
-60.27
9
A
ASP
11
-164.59
-40.96
9
A
LEU
14
-176.18
39.37
10
A
VAL
2
-129.82
-77.96
10
A
GLN
3
-151.86
-50.64
10
A
ALA
4
70.90
-179.86
10
A
ARG
5
48.83
28.93
10
A
TRP
6
-155.43
-149.84
10
A
GLU
7
-38.59
96.30
10
A
ALA
8
43.87
-97.80
10
A
ALA
9
-177.05
140.46
10
A
PHE
10
-104.35
-91.83
10
A
ASP
13
50.33
19.51
10
A
LEU
14
38.83
32.13
11
A
VAL
2
31.86
-101.77
11
A
GLN
3
-160.43
-41.08
11
A
ALA
4
49.51
171.24
11
A
TRP
6
-174.03
-151.76
11
A
GLU
7
-41.47
97.02
11
A
ALA
8
51.42
-94.25
11
A
ALA
9
174.19
134.58
11
A
PHE
10
-83.56
-75.65
11
A
ASP
11
-141.83
-77.71
11
A
ASP
13
33.84
57.24
11
A
LEU
14
-171.19
31.20
SOLUTION STRUCTURES OF SYR6
1
N
N
ANTIVIRAL PROTEIN
SYR6, ANTIVIRAL PROTEIN
BAB62415
GB
1
15076606
1
15
1ID6
1
15
15076606
A
1
1
15